Irbesartan inhibits human T-lymphocyte activation through downregulation of activator protein-1

British Journal of Pharmacology

Volumn 142, Issue 6, 2004, Pages 933-942

  Cheng, Shu Meng ^a   Yang, Shih Ping ^a   Ho, Ling Jun ^b   Tsao, Tien Ping ^a   Chang, Deh Ming ^a   Lai, Jenn Haung ^a  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

Activator protein 1; Atherosclerosis; Irbesartan; T lymphocyte

Indexed keywords

DNA; GAMMA INTERFERON; IRBESARTAN; MITOGEN ACTIVATED PROTEIN KINASE P38; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; ATHEROSCLEROSIS; BINDING AFFINITY; CYTOKINE PRODUCTION; CYTOTOXICITY; DISEASE COURSE; DNA BINDING; DOWN REGULATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TRANSCRIPTION INITIATION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BIPHENYL COMPOUNDS; BLOTTING, WESTERN; CELL SURVIVAL; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; ELECTROPHORETIC MOBILITY SHIFT ASSAY; HUMANS; HYDROGEN PEROXIDE; INTERLEUKIN-1; JNK MITOGEN-ACTIVATED PROTEIN KINASES; JURKAT CELLS; LUCIFERASES; LYMPHOCYTE ACTIVATION; NF-KAPPA B; OLIGONUCLEOTIDES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PLASMIDS; PROTEIN BINDING; T-LYMPHOCYTES; TETRAZOLES; TRANSCRIPTION FACTOR AP-1; TRANSCRIPTION, GENETIC; TRANSFECTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 3843096209     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0705785     Document Type: Article

References (75)

1. AHN, J.D., MORISHITA, R., KANEDA, Y., LEE, S.J., KWON, K.Y., CHOI, S.Y., LEE, K.U., PARK, J.Y., MOON, I.J., PARK, J.G., YOSHIZUMI, M., OUCHI, Y. & LEE, I.K. (2002). Inhibitory effects of novel AP-1 decoy oligodeoxynucleotides on vascular smooth muscle cell proliferation in vitro and neointimal formation in vivo. Circ. Res., 90, 1325-1332.
2. BARATH, P., FISHBEIN, M.C., CAO, J., BERENSON, J., HELFANT, R.H. & FORRESTER, J.S. (1990). Detection and localization of tumor necrosis factor in human atheroma. Am. J. Cardiol., 65, 297-302.
3. BERK, B.C., VEKSHTEIN, V., GORDON, H.M. & TSUDA, T. (1989). Angiotensin II-stimulated protein synthesis in cultured vascular smooth muscle cells. Hypertension, 13, 305-314.
4. BRASIER, A.R., RECINOS III, A. & ELEDRISI, M.S. (2002). Vascular inflammation and the renin-angiotensin system. Arterioscler. Thromb. Vasc. Biol., 22, 1257-1266.
5. BRUNNER, H.R. (1997). The new angiotensin II receptor antagonist, irbesartan. Am. J. Hypertens., 10, 311S-317S.
6. CHENG, S.M., YANG, S.P., HO, L.J., TSAO, T.P., JUAN, T.Y., CHANG, D.M., CHANG, S.Y. & LAI, J.H. (2003). Down-regulation of c-jun N-terminal kinase-activator protein-1 signaling pathway by Ginkgo biloba extract in human peripheral blood T cells. Biochem. Pharmacol., 66, 679-689.
7. CHUA, C.C., HAMDY, R.C. & CHUA, B.H.L. (1998). Upregulation of vascular endothelial growth factor by angiotensin II on rat heart endothelial cells. Biochim. Biophys. Acta, 1401, 187-194.
8. CONSTANTINESCU, C.S., GOODMAN, D.B. & VENTURA, E.S. (1998). Captopril and lisinopril suppress production of interleukin-12 by human peripheral blood mononuclear cells. Immunol. Lett., 62, 25-31.
9. DOL, F., MARTIN, G., STAELS, B., MARES, A.M., CAZAUBON, C., NISATO, D., BIDOUARD, J.P., JANIAK, P., SCHAEFFER, P. & HERBERT, J.M. (2001). Angiotensin AT1 receptor antagonist irbesartan decreases lesion size, chemokine expression, and macrophage accumulation in apolipoprotein-E-deficient mice. J. Cardiovasc. Pharmacol., 38, 395-405.
10. DOLLERY, C.M., MCEWAN, J.R. & HEMMEY, A.M. (1995). Matrix metalloproteinases and cardiovascular disease. Circ. Res., 77, 863-868.
11. FLEET, J.C., CLINTON, S.K., SALOMON, R.N., LOPPNOW, H. & LIBBY, P. (1992). Atherogenic diets enhance endotoxin-stimulated interleukin-1 and tumor necrosis factor gene expression in rabbit aortae. J. Nutr., 122, 294-305.
12. FLEISCHER, J., SOETH, E., REILING, N., GRAGE-GRIEBENOW, E., FLAD, H.D. & ERNST, M. (1996). Differential expression and function of CD80 (B7-1) and CD86 (B7-2) on human peripheral blood monocytes. Immunology, 89, 592-598.
13. GALIS, Z.S., MUSZYNSKI, M. & SUKHOVA, G.K. (1994). Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion. Circ. Res., 75, 181-189.
14. GENG, Y.J., HOLM, J., NYGREN, S., BRUZELIUS, M., STEMME, S. & HANSSON, G.K. (1995). Expression of the macrophage scavenger receptor in atheroma. Relationship to immune activation and the T-cell cytokine interferon-gamma. Arterioscler. Thromb. Vasc. Biol., 15, 1095-1102.
15. GERTZBERG, N., CLEMENTS, R., JASPERS, I., FERRO, T.J., NEUMANN, P., FLESCHER, E. & JOHNSON, A. (2000). Tumor necrosis factor-α-induced activating protein-1 activity is modulated by nitric oxide-mediated protein kinase G activation. Am. J. Resp. Cell Mol. Biol., 22, 105-115.
16. GILSTON, V., WILLIAMS, M.A., NEWLAND, A.C. & WINYARD, P.G. (2001). Hydrogen peroxide and tumor necrosis factor-alpha induce NF-kappa B-DNA binding in primary human T lymphocytes in addition to T cell lines. Free Radic. Res., 35, 681-691.
17. GODSEL, L.M., LEON, J.S., WANG, K., FORNEK, J.L., MOLTENI, A. & ENGMAN, D.M. (2003). Captopril prevents experimental autoimmune myocarditis. J. Immunol., 171, 346-352.
18. GRIENDLING, K.K., MINIERI, C.A., OLLERENSHAW, J.D. & ALEXANDER, R.W. (1994). Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ. Res., 74, 1141-1148.
19. HANSSON, G.K., HELLSTRAND, M., RYMO, L., RUBBIA, L. & GABBIANI, G. (1989a). Interferon-γ inhibits both proliferation and expression of differentiation-specific α-smooth muscle actin in arterial smooth muscle cells. J. Exp. Med., 170, 1595-1608.
20. HANSSON, G.K., HOLM, J. & JONASSON, L. (1989b). Detection of activated T lymphocytes in the human atherosclerotic plaque. Am. J. Pathol., 135, 169-175.
21. HARRISON, D.G. (1997). Cellular and molecular mechanisms of endothelial cell dysfunction. J. Clin. Invest., 100, 2153-2157.
22. HAVRANEK, E.P., THOMAS, I., SMITH, W.B., PONCE, G.A., BILSKER, M., MUNGER, M.A. & WOLF, R.A. (1999). Dose-related beneficial long-term hemodynamic and clinical efficacy of irbesartan in heart failure. J. Am. Coll. Cardiol., 33, 1174-1181.
23. HOPE, S., BRECHER, P. & CHOBANIAN, A.V. (1999). Comparison of the effects of AT1 receptor blockade and angiotensin converting enzyme inhibition on atherosclerosis. Am. J. Hypertens., 12, 28-34.
24. HU, Y., ZOU, Y., DIETRICH, H., WICK, G. & XU, Q. (1999). Inhibition of neointima hyperplasia of mouse vein grafts by locally applied suramin. Circulation, 100, 861-868.
25. JORMSJÖ, S., YE, S., MORITZ, J., WATER, D.H., DIMMELER, S., ZEIHER, A.M., HENNEY, A., HAMSTERN, A. & ERIKSSON, P. (2000). Allele-specific regulation of matrix metalloproteinase-12 gene activity is associated with coronary artery luminal dimensions in diabetic patients with manifest coronary artery disease. Circ. Res., 86, 998-1003.
26. JUNE, C.H., LEDBETTER, J.A., LINSLEY, P.S. & THOMPSON, C.B. (1990). Role of the CD28 receptor in T-cell activation. Immunol. Today, 11, 211-216.
27. KALRA, D., SIVASUBRAMANIAN, N. & MANN, D.L. (2002). Angiotensin II induces tumor necrosis factor biosynthesis in the adult mammalian heart through a protein kinase C-dependent pathway. Circulation, 105, 2198-2205.
28. KARIN, M., LIU, Z. & ZANDI, E. (1997). AP-1 function and regulation. Curr. Opin. Cell Biol., 9, 240-246.
29. KEIDAR, S., ATTIAS, J., SMITH, J., BRESLOW, J. & HAYEK, T. (1997). The angiotensin-II receptor antagonist, losartan, inhibits LDL lipid peroxidation and atherosclerosis in apolipoprotein E-deficient mice. Biochem. Biophys. Res. Commun., 236, 622-625.
30. KHAN, B.V., NAVALKAR, S., KHAN, Q.A., RAHMAN, S.T. & PARTHASARATHY, S. (2001). Irbesartan, an angiotensin type I receptor inhibitor, regulates the vascular oxidative state in patients with coronary artery disease. J. Am. Coll. Cardiol., 38, 1662-1667.
31. KINTSCHER, U., WAKINO, S., KIM, S., FLECK, E., HSUEH, W.A. & LAW, R.E. (2001). Angiotensin II induces migration and pyk2/ paxillin phosphorylation of human monocytes. Hypertension, 37, 587-593.
32. KISHIKAWA, H., SHIMOKAMA, T. & WATANABE, T. (1993). Localization of T lymphocytes and macrophages expressing IL-1, IL-2 receptor, IL-6 and TNF in human aortic intima: role of cell-mediated immunity in human atherogenesis. Virchows Arch. A Pathol. Anat. Histopathol., 423, 433-442.
33. KLAHR, S. & MORRISSEY, J. (1998). Angiotensin II and gene expression in the kidney. Am. J. Kidney Dis., 31, 171-176.
34. KRANZHOFER, R., BROWATZKI, M., SCHMIDT, J. & KUBLER, W. (1999). Angiogensin II activates the proinflammatory transcription factor nuclear factor-κB in human monocytes. Biochem. Biophys. Res. Commun., 257, 826-828.
35. KUNSCH, C. & MEDFORD, R.M. (1999). Oxidative stress as a regulator of gene expression in the vasculature. Circ. Res., 85, 753-766.
36. KYRIAKIS, J.M. (1999). Activation of the AP-1 transcription factor by inflammatory cytokines of the TNF family. Gene Expr., 7, 217-231.
37. LAI, J.H., HO, L.J., KWAN, C.Y., CHANG, D.M. & LEE, T.C. (1999). Plant alkaloid tetrandrine and its analog block CD28-costimulated activities of human peripheral blood T cells: potential immunosuppressants in transplantation immunology. Transplantation, 68, 1383-1392.
38. LAI, J.H., HORVATH, G., SUBLESKI, J., BRUDER, J., GHOSH, P. & TAN, T.H. (1995). RelA is a potent transcriptional activator of the CD28 response element within the interleukin 2 promoter. Mol. Cell. Biol., 15, 4260-4271.
39. LANIER, L.L., O'FALLON, S., SOMOZA, C., PHILLIPS, J.H., LINSLEY, P.S., OKUMURA, K., ITO, D. & AZUMA, M. (1995). CD80 (B7) and CD86 (B70) provide similar costimulatory signals for T cell proliferation, cytokine production, and generation of CTL. J. Immunol., 154, 97-105.
40. LARRICK, J.W. & WRIGHT, S.C. (1990). Cytotoxic mechanism of tumor necrosis factor-α. FASEB J., 4, 3215-3223.
41. LAURAT, E., POIRIER, B., TUPIN, E., CALIGIURI, G., HANSSON, G.K., BARIETY, J. & NICOLETI, A. (2001). In vivo downregulation of T helper cell 1 immune responses reduces atherogenesis in apolipoprotein E-knockout mice. Circulation, 104, 197-202.
42. LEVINE, B.L., UEDA, Y., CRAIGHEAD, N., HUANG, M.L. & JUNE, C.H. (1995). CD28 ligands CD80 (B7-1) and CD 86 (B7-2) induce long-term autocrine growth of CD4+ T cells and induce similar patterns of cytokine secretion in vitro. Int. Immunol., 7, 891-904.
43. LI, H., FREEMAN, M.W. & LIBBY, P. (1995). Regulation of smooth muscle cell scavenger receptor expression in vivo by atherogenic diets and in vitro by cytokines. J. Clin. Invest., 95, 122-133.
44. LI, P., FUKUHARA, M., DIZ, D.I., FERRARIO, C.M. & BROSNIHAN, K.B. (2000). Novel angiotensin II AT(1) receptor antagonist irbesartan prevents thromboxane A(2)-induced vasoconstriction in canine coronary arteries and human platelet aggregation. J. Pharmacol. Exp. Ther., 292, 238-246.
45. LIBBY, P. & HANSSON, G.K. (1991). Involvement of the immune system in human atherogenesis: current knowledge and unanswered questions. Lab. Invest., 64, 5-15.
46. LIN, J.H.C., ZHU, Y., LIAO, H.L., KOBARI, Y., GROSZEK, L. & STEMERMAN, M.B. (1996). Induction of vascular cell adhesion molecule-1 by low-density lipoprotein. Atherosclerosis, 127, 185-194.
47. LO, Y.Y.C. & CRUZ, T.F. (1995). Involvement of reactive oxygen species in cytokine and growth induction of c-fos expression in chondrocytes. J. Biol. Chem., 270, 11727-11730.
48. LONN, E.M., YUSUF, S., JHA, P., MONTAGUE, T.J., TEO, K.K., BENEDICT, C.R. & PITT, B. (1994). Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation, 90, 2056-2069.
49. MAGGI-CAPEYRON, M.F., CEBALLOS, P., CRISTOL, J.P., DELBOSC, S., LE DOUCEN, C., PONS, M., LEGER, C.L. & DESCOMPS, B. (2001). Wine phenolic antioxidants inhibit AP-1 transcriptional activity. J. Agric. Food Chem., 49, 5646-5652.
50. 2 and antioxidants have opposite effects on activation of NF-kappa B and AP-1 in intact cells: AP-1 as secondary antioxidant-responsive factor. EMBO J., 12, 2005-2015.
51. MIHM, S., GALTER, D. & DROGE, W. (1995). Modulation of transcription factor NF-κB activity by intracellular glutathine levels and by variations of the extracellular cysteine supply. FASEB J., 9, 246-252.
52. MOSMANN, T. (1983). Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods, 65, 55-63.
53. MOYER, C.F., SAJUTHI, D., TULLI, H. & WILLIAMS, J.K. (1992). Synthesis of IL-1α and IL-1β by arterial cells in atherosclerosis. Am. J. Pathol., 138, 951-960.
54. NAVALKAR, S., PARTHASARATHY, S., SANTANAM, N. & KHAN, B.V. (2001). Irbesartan, an angiotensin type 1 receptor inhibitor, regulates markers of inflammation in patients with premature atherosclerosis. J. Am. Coll. Cardiol., 37, 440-444.
55. PEETERS, A.C., NETEA, M.G., KULLBERG, B.J., THIEN, T. & VAN DER MEER, J.W. (1998). The effect of renin-angiotensin system inhibitors on pro- and anti-inflammatory cytokine production. Immunology, 94, 376-379.
56. PETROV, V.V., FAGARD, R.H. & LIJNEN, P.J. (2001a). Long-term treatment with enalapril or losartan does not show antiproliferative effects in peripheral blood mononuclear cells. Methods Find. Exp. Clin. Pharmacol., 23, 149-152.
57. PETROV, V.V., FAGARD, R.H. & LIJNEN, P.J. (2001b). T-lymphocyte and plasma angiotensin-converting enzyme activity during enalapril and losartan administration in humans. J. Cardiovasc. Pharmacol., 38, 578-583.
58. RIVARD, A., PRINCIPE, N. & ANDRES, V. (2000). Age-dependent increase in c-fos activity and cyclin A expression in vascular smooth muscle cells. A potential link between aging, smooth muscle cell proliferation and atherosclerosis. Cardiovasc. Res., 45, 1026-1034.
59. ROSS, R. (1999). Atherosclerosis an inflammatory disease. N. Engl. J. Med., 340, 115-126.
60. RODRIGUEZ-ITURBE, B., PONS, H., HERRERA-ACOSTA, J. & JOHNSON, R.J. (2001). Role of immunocompetent cells in nonimmune renal diseases. Kidney Int., 59, 1626-1640.
61. RUS, H.G., NICULESCU, F. & VLAICU, R. (1991). Tumor necrosis factor-alpha in human arterial wall with atherosclerosis. Atherosclerosis, 89, 247-254.
62. SAKAMOTO, H., AIKAWA, M., HILL, C.C., WEISS, D., TAYLOR, W.R., LIBBY, P. & LEE, R.T. (2001). Biomechanical strain induces class A scavenger receptor expression in human monocyte/macrophages and THP-1 cells. Circulation, 104, 109-114.
63. SCHIFFRIN, E.L. (2002). Vascular changes in hypertension in response to drug treatment: effects of angiotensin receptor blockers. Can. J. Cardiol., 18 (Suppl A), 15A-18A.
64. SONMEZ, A., KISA, U., UCKAYA, G., EYILETEN, T., COMERT, B., KOC, B., KOCABALKAN, F. & OZATA, M. (2001). Effects of losartan treatment on T-cell activities and plasma leptin concentrations in primary hypertension. JRAAS, 2, 112-116.
65. STEMME, S. & HANSSON, G.K. (1994). Immune mechanisms in atherogenesis. Ann. Med., 26, 141-146.
66. STRAWN, W.B., GALLAGHER, P.E., TALLANT, A., GANTEN, D. & FERRARIO, C.M. (1999). Angiotensin II ATI-receptor blockade inhibits monocyte activation and adherence in transgenic (mRen2) 27 rats. J. Cardiovasc. Pharmacol., 33, 341-351.
67. 2 for platelet-derived growth factor signal transduction. Science, 270, 296-299.
68. TIMMERMANS, P.B., WONG, P.C., CHIU, A.T., HERBLIN, W.F., BENFIELD, P., CARINI, D.J., LEE, R.J., WEXLER, R.R., SAYE, J.A. & SMITH, R.D. (1993). Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol. Rev., 45, 205-251.
69. TINTUT, Y., PATEL, J., PARHAMI, F. & DEMER, L.L. (2000). Tumor necrosis factor-α promotes in vitro calcification of vascular cells via the cAMP pathway. Circulation, 102, 2636-2642.
70. USHIO-FUKAI, M., ZAFARI, A.M., FUKUI, T., ISHIZAKA, N. & GRIENDLING, K.K. (1996). P22phox is a critical component of superoxide-generating NADH/NADPH oxidase system and regulates angiotensin II-induced hypertrophy in vascular smooth muscle cells. J. Biol. Chem., 271, 23317-23321.
71. VIEDT, C., VOGEL, J., ATHANASIOU, T., SHEN, W., ORTH, S.R., KUBLER, W. & KREUZER, J. (2002). Monocyte chemoattractant protein-1 induces proliferation and interleukin-6 production in human smooth muscle cells by differential activation of nuclear factor-kappaB and activator protein-1. Arterioscler. Thromb. Vasc. Biol., 22, 914-920.
72. XANTHOUDAKIS, S., MIAO, G.G. & CURRAN, T. (1994). The redox and DNA-repair activities of Ref-1 are encoded by nonoverlapping domains. Proc. Natl. Acad. Sci. U.S.A., 91, 23-27.
73. YANG, S.P., HO, L.J., LIN, Y.L., CHENG, S.M., TSAO, T.P., CHANG, D.M., HSU, Y.L., SHIH, C.Y., JUAN, T.Y. & LAI, J.H. (2003). Carvedilol, a new antioxidant β-blocker, blocks in vitro human peripheral blood T cell activation by downregulation NF-êB activity. Cardiovasc. Res., 59, 776-737.
74. ZHAO, S.P. & XIE, X.M. (2001). Captopril inhibits the production of tumor necrosis factor-alpha by human mononuclear cells in patients with congestive heart failure. Clin. Chim. Acta, 304, 85-90.
75. + T cells aggravates atherosclerosis in immuno-deficient apolipoprotein E knockout mice. Circulation, 102, 2919-2922.